Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 625 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Bioniche terminates Phase III bladder cancer trial

Endo Pharmaceuticals, Bioniche’s licensing partner, was conducting the randomized, active-controlled trial. According to Bioniche, the study was not being recruited at the anticipated rate and subsequent to the

Novavax reports wider Q3 net loss

Revenue for third quarter of 2012 was $5.76m compared to $5.01m for the third quarter of 2011. The company reported a net loss of $20.47m, or $0.16 per